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ABSTRACT
Introduction: The standard of care for reversal
of opioid-induced respiratory depression
associated with opioid overdose is injectable
naloxone. This study compared the usability of
two naloxone delivery devices, a naloxone auto-
injector (NAI) and a naloxone intranasal
delivery system (NXN), in the administration
of naloxone during a simulated opioid overdose
emergency. NAI (EVZIO; kaleo, Inc.,
Richmond, VA, USA) is a Food and Drug
Administration approved single-use pre-filled
auto-injector containing 0.4 mg of naloxone.
Methods: Study participants were randomly
assigned to administer naloxone using NAI
and NXN, sequentially. The primary endpoint
was successful administration of a simulated
dose of naloxone into a mannequin during a
simulated opioid emergency, both before and
after receiving training. Secondary endpoints
included using the NAI or NXN in accordance
with the instructions-for-use and the
comparative measurement of successful
completion time of administration for both
NAI and NXN.
Results: A total of 42 healthy participants aged
18–65 years were enrolled in the study. The
proportion of participants able to successfully
administer a simulated dose of naloxone was
significantly greater for NAI compared to NXN
both before (90.5% vs. 0.0%, respectively,
P\0.0001) and after (100% vs. 57.1%,
respectively, P\0.0001) participant training.
The proportion of participants able to
administer a simulated dose of naloxone in
accordance with the instructions-for-use was
also significantly greater for NAI compared to
NXN before (85.7% vs. 0.0%, respectively,
P\0.0001) and after (100% vs. 0.0%,
respectively, P\0.0001) participant training.
The average time to task completion for
administration attempt before training was
0.9 ± 0.25 min for NAI versus 6.0 ± 4.76 min
for NXN and after training was 0.5 ± 0.15 min
for NAI versus 2.0 ± 2.15 min for NXN.
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Conclusion: Laypersons experienced
substantially greater success administering a
simulated dose of naloxone, both before and
after training, using NAI versus NXN during a
simulated opioid overdose emergency. No
participants correctly used NXN without
training.
Keywords: Design validation; Human factors;
Human factors engineering; Naloxone auto-
injector (NAI); Naloxone atomization kit;
Opioid overdose; Simulated use; Use error
INTRODUCTION
Over the last decade, opioid-related deaths have
increased at an alarming rate resulting in a
growing public health concern in the United
States. There were more than four times as many
opioid-related fatalities in 2010 as there were in
1999 [1] and opioid-related fatalities have
remained at these levels through 2013 [2–4].
This increase coincided with a nearly fourfold
increase in the use of prescribed opioids for the
treatment of pain [5]. Naloxone hydrochloride
injection, used for four decades by trained
emergency response personnel, is the first-line
treatment to reverse life-threatening opioid-
induced respiratory depression (OIRD) and
overdose [6, 7].
In the 1990s researchers began to investigate
off-label administration of parenteral
formulations of naloxone via the intranasal
route of delivery and emergency medical
technician units initiated pre-hospital
intervention protocols using the intranasal
route of naloxone administration in the early
2000s [8]. To further combat the growing opioid
overdose crisis, members of the Harm
Reduction Community began distributing
naloxone nasal atomization kits (NXN) [9].
These organizations provide instructional
sessions attended typically by the at-risk
opioid users who are then expected to
subsequently train their life partners,
caregivers, or family members on the correct
assembly and use of the kit.
The NXN consists of a glass cartridge
containing a parenteral formulation of
naloxone, a nasal atomizer (e.g., LMA MAD
NasalTM [10]; Teleflex Inc., Morrisville, NC,
USA), personal protective equipment, and
instructions-for-use. The instructions specify
that the naloxone should be administered into
each nostril of an individual suffering from
OIRD. The intranasal route of naloxone
administration is not approved by the United
States Food and Drug Administration (FDA).
Therefore, use of this intranasal naloxone kit is
considered an off-label use of naloxone.
Additionally, the limited availability of
naloxone combined with the level of training
required to ensure correct assembly and use of
the kit has been a barrier for wider community
access to this potentially life-saving drug [11].
A novel naloxone auto-injector (NAI),
EVZIO (naloxone hydrochloride injection;
kaleo, Inc., Richmond, VA, USA), was
specifically developed using state-of-the-art
human factors engineering to address this
unmet medical need. NAI was developed for
immediate administration, with little to no
training, by family members or caregivers of
opioid overdose victims during an opioid
emergency outside of a medically supervised
setting. NAI provides voice instructions that
assist in guiding the user through
administration of a 0.4 mg dose of naloxone
hydrochloride injection and contains a
retractable needle system that conceals the
needle before, during and after administration.
NAI was granted fast track designation and a
priority review by the FDA. NAI is indicated for
the emergency treatment of known or
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suspected opioid overdose as manifested by
central nervous system or respiratory
depression and is intended for immediate
administration as emergency therapy in
settings where opioids may be present [12].
Various organizations have suggested that
the NXN kits are easy to use and may not
require training [13]; however, no usability
studies have been reported that evaluate the
use of NXN kits without training or the
ability of individuals to retain what they
learned during training to successfully
administer a dose of naloxone during an
opioid emergency. A recent study reported
an evaluation of the use of NXN in trained
and untrained users in a community setting.
However, this evaluation was not specifically
designed to evaluate correct use of NXN,
usability of NXN, or responder’s adherence
to instructions [11].
This is the first known study conducted to
evaluate the usability of NXN as compared to
NAI during a simulated opioid overdose
emergency by participants without training
and following one-on-one training sessions by
a healthcare professional. This study was
conducted by a third-party contract research
organization whose specialty is human factors
investigation and residual risk analysis.
METHODS
Participants
Healthy adult participants who were not
severely visually impaired or hearing impaired
were eligible to enroll. All participants were
English language proficient. The participants
had no prior experience with using, or being
trained on, any naloxone delivery products and
no relevant experience with similar nasal or
injection delivery systems.
Study Materials
NXN were purchased and consisted of one
carton of naloxone hydrochloride for
injection, USP (International Medical Systems
Ltd., South El Monte, CA, USA; NDC
76329-3369-1) and LMA MAD Nasal Device
contained within a plastic bag. Evzio (NDC
60842-030-01) were obtained from kaleo, Inc.
NXN and NAI are shown in Figs. 1 and 2,
respectively. A full size adult mannequin was
used to simulate a patient experiencing an
opioid emergency.
Study Objectives
The primary objective of the study was to
compare the usability of NAI and NXN in the
administration of naloxone during a simulated
opioid overdose emergency. The primary
endpoint was successful administration of a
simulated dose of naloxone into a simulated
patient (mannequin) before and after receiving
training without committing a Critical Task
Error. Critical Task Error was defined as an error
in essential task steps required to administer a
clinically meaningful dose of naloxone
successfully. The secondary endpoints were
using the NAI or NXN in accordance with
their instructions-for-use and the completion
time of administration for NAI or NXN. Critical
Task Errors, errors in adherence to instructions,
and time to completion were measured.
Subjective feedback was obtained for NXN and
NAI after each use phase to facilitate evaluation
of these errors and user preferences for each
product.
Study Design
This was a single-site, randomized, open-label
study. The study included three different
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phases. In phase 1, study participants were
presented with brief information on the use
scenario, but were not provided any training on
the use of the two products. The use
environment simulated a home setting
including chairs, coffee table, and the
mannequin (simulated patient) located on a
couch randomly assigned to face-up or face-
Fig. 1 Naloxone nasal atomization kit (LMA MAD
NasalTM; Teleﬂex Inc., Morrisville, NC, USA) components
and packaging. In descending order: Outer packaging for
naloxone and delivery syringe (top); plastic delivery syringe;
glass vial of naloxone hydrochloride; nasal atomization
device; packaging for nasal atomization device (bottom left)
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down orientation. To add distraction and
induce stress, a movie played on a television
screen in the background. The participant was
observed with the use of several cameras and
two investigators located within the simulated
environment. The investigators documented
the participant’s administration using each
product (randomly assigned) into a simulated
patient experiencing an opioid overdose. No
training was provided to participants prior to or
during phase 1 and participants could only rely
on the instructions-for-use found on the
products themselves and no additional
instructional materials (e.g., instruction-for-use
leaflets, etc.) were present.
In phase 2 of the study, each participant
received training from a healthcare professional
(nurse) on the use of each product. Training
included having each participant demonstrate
correct use of NAI and NXN.
For phase 3, at 7 or 8 days after the training
session, the participants returned to attempt to
administer naloxone to a simulated patient
mannequin using NAI and NXN during a
simulated opioid overdose emergency. No
additional training was provided during phase
3. Participants were expected to rely on their
recall of training to demonstrate correct use of
the products. Participants were monitored by
two investigators for compliance with critical
tasks and adherence to instructions-for-use.
Participants were videotaped to archive their
performances during both simulated use phases
of the study. Either investigator was permitted
to terminate a simulation if the participant
posed a safety risk to himself or herself.
Fig. 2 Naloxone 0.4 mg auto-injector (naloxone hydrochloride injection, USP; EVZIO; kaleo, Inc., Richmond, VA, USA)
outer case (left) and device (right)
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Study Oversight
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in
2013. Informed consent was obtained from all
participants included in the study. The study
was performed by UL-Wiklund Research &
Design and was conducted under the review
and approval of the Allendale Investigational
Review Board. Study participants were blinded
to study funding which was provided by kaleo,
Inc.
Assessments of Usability
The participants were assessed for their ability
to complete a successful administration of
naloxone into a mannequin using both NAI
and NXN. There were two simulation sessions
during the study; during phase 1, participants
were presented with an opioid overdose
emergency scenario of a simulated living room
environment with distractions (e.g., observers,
television playing in the background), with the
simulated overdose victim mannequin lying on
a couch. With no prior training, participants
were instructed to administer a simulated dose
of naloxone into the mannequin after being
presented with each naloxone product, NAI and
NXN. Participants could only rely on the
instructions-for-use found on the products
themselves and no additional materials (e.g.,
instructions-for-use, leaflets, etc.) were present.
Immediately following phase 1, each
participant received one-on-one training for
each product from a nurse and had to
demonstrate correct use in accordance with
instructions (phase 2). Seven to eight days
post-training, the participants returned for
phase 3 and repeated the identical opioid
emergency scenario simulation with both
naloxone delivery products. For each session,
participants were given a maximum of 15 min
to complete each administration.
Completion time was assessed from the time
each product was provided to the participant
and the investigator indicated ‘start’ to the time
the participant completed administration of
product, verbally stated ‘finished’ or after
15 min (maximum time allowed). In cases
where the tasks could not be completed (i.e.,
the user gave up or the simulation was
terminated due to time), the participant’s time
was imputed with a value of 15 min.
Evaluation of Usability and
Administration During Phase 1
and Phase 3
Correct use of medical products, including
drug/device combination products can be
defined as compliance with critical tasks or
adherence to instructions. Adherence to
instructions is a measure of using the product
as intended, including adherence to steps that
may not strictly be required to deliver a
clinically meaningful dose of naloxone.
Critical tasks for this study were those steps
that are required to ensure successful naloxone
administration resulting in a clinically
meaningful dose of naloxone available for
systemic absorption. For example, for NAI, the
drug is indicated for subcutaneous or
intramuscular use and the instructions-for-use
states to inject into the outer thigh. However,
an injection into commonly accepted
subcutaneous or intramuscular locations of the
abdomen, thigh, deltoid, or buttocks would be
expected to deliver an effective dose. Therefore,
if a participant injected NAI into the deltoid of
the mannequin, it would be coded as a use error
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for adherence to the instructions-for-use, but
not as a critical use error. Similarly, for NXN,
the instructions-for-use indicates administering
exactly half the dose (1 mL) into each nostril;
however, this may not be required to achieve a
clinically meaningful effective dose. Therefore,
the critical task for NXN was defined as
administering any quantity of naloxone into
both nostrils, assuming that some exposure to
both nostrils would permit absorption of a
sufficient quantity of naloxone from the nasal
mucosa.
Statistical Analyses
Descriptive statistics were calculated to
summarize continuous measures. Frequency
count/percentages were used for summarizing
categorical measures. For each product, the
proportions of participants who would have
successfully administered a clinically
meaningful dose were reported as counts and
percentages. Success was defined as not
committing any use errors on each product’s
critical tasks as presented in Table 1 as well as
the ability to use each product according to the
product’s instructions-for-use as presented in
Table 2.
The ability to administer NAI and NXN in
accordance with each product’s instructions-
for-use was also assessed and reported as counts
and percentages.
McNemar’s test was performed for
comparison of critical task success as well as
adherence to instructions-for-use success for
NAI and NXN between phase 1 and phase 3.
Wilcoxon rank-sum test performed as
sensitivity analysis for time to task completion
for comparison between NAI and NXN within
each phase (phase 1 and phase 3), and NAI or
NXN between phase 1 and phase 3.
RESULTS
Participants
A total of 42 healthy participants between 18 and
65 years of age were enrolled in this study. The
demographics and baseline characteristics of the
participants are shown in Table 3. The mean age
was 41 ± 13.4 years for the participants. There
were 45.2%male and 54.8% female participants.
All 42 participants completed the study.
Usability and Administration
of NAI and NXN
During phase 1, 90.5% of participants
completed a successful injection using NAI on
the first attempt with no prior training or
instruction leaflets versus 0.0% using NXN for
the simulated opioid overdose scenario
(P\0.0001).
Phase 2 resulted in all participants
successfully completing a one-on-one training
session with a nurse, which included each
participant demonstrating successful use of
each naloxone product. Seven to eight days
after the training session, participants returned
for phase 3 and repeated the simulation.
During phase 3, 100% of participants
successfully administered a simulated
naloxone dose using NAI versus only 57.1%
using NXN (P\0.0001).
Task completion time for NAI was
0.9 ± 0.25 min for phase 1 (untrained) and
0.5 ± 0.15 min for phase 3 (post-training).
NXN task completion time for phase 1 was
6.0 ± 4.76 min and 2.0 ± 2.15 min for phase 3.
Participant Completion of Critical Tasks
Each product’s critical tasks are detailed in
Table 1. During the phase 1 opioid emergency
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simulation (i.e., no training or instructional
reference materials provided), 38 out of 42
participants (90.5%) successfully administered
a simulated dose of naloxone with NAI
compared to 0 out of 42 participants (0.0%)
with NXN (P\0.0001).
During the phase 3 opioid overdose
emergency simulation (i.e., after training), 42
Table 1 Critical tasks for NAI and NXN
NAI critical tasks NXN critical tasksa
(1) Remove from outer case (1) Pull off both yellow caps from syringe
(2) Pull off red safety guard (2) Pull off purple naloxone cap from naloxone cartridge
(3) Place black end onto patient’s appropriate
injection locationb
(3) Attach atomizer onto syringe
(4) Press ﬁrmly to activate (4) Screw naloxone cartridge into syringe
(5) Hold at least 1 s (5) Assemble the cartridge or atomizer without
any drug leaking prematurelyc
(6) Place atomizer tip into patient’s nostril
(7) Push cartridge to administer some naloxone into one nostril
(8) Push cartridge to administer remaining naloxone into the other nostril
NAI naloxone 0.4 mg auto-injector, NXN naloxone nasal atomization kit
a Participants can perform steps 1–2 and 3–4 out of sequence
b Locations include subcutaneous or intramuscular injection into abdomen, thigh, arm, buttocks
c Drug leaking deﬁned as naloxone leaking between atomizer and syringe, from the back of the cartridge, or due to cartridge
breaking
Table 2 Adherence to instructions-for-use for NAI and NXN
NAI instructions NXN instructionsa
(1) Remove from outer case (1) Remove medication and atomizer
(2) Pull off red safety guard (2) Pull off both yellow caps from syringe
(3) Place black end onto patient’s outer thigh (3) Pull off purple naloxone cap from naloxone cartridge
(4) Press ﬁrmly to activate (4) Attach atomizer onto syringe by the hold wings on the atomizer
(5) Hold for at least 5 s (5) Screw naloxone cartridge into syringe
(6) Place atomizer tip into patient’s nostril
(7) Push cartridge to administer some naloxone into one nostril
(8) Push cartridge to administer approximately 1 mL
naloxone into the other nostril
NAI naloxone 0.4 mg auto-injector, NXN naloxone nasal atomization kit
a Participants can perform steps 2–3 and 4–5 out of sequence
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out of 42 participants (100%) successfully
administered a simulated dose of naloxone
with NAI compared to 24 out of 42
participants (57.1%) with NXN (P\0.0001).
The proportion of participants who
successfully administered a simulated dose of
naloxone with NXN was significantly
(P\0.0001) greater in phase 3 (i.e., post-
training) than in phase 1 (i.e., no training).
The results are summarized in Table 4.
The Critical Task Errors for NAI and NXN are
shown in Table 5. During phase 1 there were
four Critical Task Errors for NAI. One error
involved injection into an incorrect muscle, the
calf, and three individuals failed to hold the
auto-injector in place after the injection for at
least one second. There were no Critical Task
Errors for NAI during the phase 3 simulations.
For NXN, there were a total of 110 Critical
Task Errors during Phase 1 simulations. None of
the participants attempted to administer
naloxone into both nostrils and 35 failed to
administer naloxone into a single nostril. In
addition, 32 participants leaked drug during
assembly, 7 did not assemble the naloxone
cartridge into the syringe correctly, 27 failed to
attach the atomizer to the syringe, and 2 did not
remove the yellow protective caps from the
syringe.
For phase 3 simulations with NXN, there
were 31 Critical Task Errors, which included 15
Table 3 Participant demographics
Characteristic Participants (n5 42)
Age (years)
Mean (SD) 41.0 (13.38)
Median 43.5





High School degree 10 (23.8%)
Associate’s degree 5 (11.9%)
Bachelor’s degree 22 (52.4%)
Master’s degree 4 (9.5%)







Participant wears glasses 15 (35.7%)
Participant has hearing aid 0 (0.0%)
Participant is color blind 0 (0.0%)
Table 4 Critical task success for NAI and NXN







Successfully completed critical NAI tasks
Yes 38 (90.5%) 42 (100.0%) 0.1250
No 4 (9.5%) 0 (0.0%)
Successfully completed critical NXN tasks
Yes 0 (0.0%) 24 (57.1%) \0.0001







NAI naloxone 0.4 mg auto-injector, NXN naloxone nasal
atomization kit
a McNemar’s Test
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failures to administer naloxone to the second
nostril, 8 failures to administer naloxone into
either nostril, 9 incidences of drug leakage
during assembly, 4 errors attaching the
naloxone cartridge to the syringe correctly,
and 3 errors attaching the atomizer to the
syringe correctly. Because of the sequential
nature of the assembly and administration
process, some errors precipitated additional
use errors for NXN.
Participant Adherence to
Instructions-for-Use
The instructions-for-use for each product are
shown in Table 2. In phase 1 (i.e., before
training), 36 of 42 (85.7%) participants
successfully administered a simulated dose of
naloxone according to its instructions-for-use
with NAI versus 0 of 42 (0.0%) with NXN
(P\0.0001).
In phase 3 (i.e., post-training), 42 of 42
(100%) participants successfully administered a
simulated dose of naloxone according to its
instructions-for-use with NAI versus 0 of 42
(0.0%) with NXN (P\0.0001). The proportion
of participants who successfully administered a
simulated dose of naloxone with NAI according
to its instructions-for-use was significantly
(P\0.0313) greater in phase 3 (i.e., post-
training) than in phase 1 (i.e., no training).
The results are summarized in Table 6.
The use errors associated with failure to
adhere to the instructions-for-use are shown
in Table 7. There were six errors in
adherence to instructions for using NAI
during phase 1; in addition to the NAI
Critical Task errors, two individuals held
Table 5 Critical use errors for NAI and NXN
Summary Phase 1 Phase 3
Total participants (n) 42 42
NAI task completion
Remove from outer case 42 (100.0%) 42 (100.0%)
Pull off red safety guard 42 (100.0%) 42 (100.0%)
Place black end against muscle 41 (97.6%) 42 (100.0%)
Press ﬁrmly to activate 42 (100.0%) 42 (100.0%)
Hold for at least 1 s 39 (92.9%) 42 (100.0%)
NXN task completion
Remove yellow caps from syringe 40 (95.2%) 42 (100.0%)
Remove purple cap from the naloxone cartridge 42 (100.0%) 42 (100.0%)
Attach atomizer to the syringe 15 (35.7%) 39 (92.9%)
Twist or screw naloxone cartridge into syringe 35 (83.3%) 38 (90.5%)
No drug leak during assembly 10 (23.8%) 33 (78.6%)
Push cartridge to administer naloxone 7 (16.7%) 34 (81.0%)
Push remaining cartridge into other nostril 0 (0.0%) 27 (64.3%)
NAI naloxone 0.4 mg auto-injector, NXN naloxone nasal atomization kit
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Table 6 Adherence to instructions-for-use success for NAI and NXN
Summary Phase 1 Phase 3 Comparison
between phasesa
Total participants (n) 42 42
Successfully completed NAI tasks
per instructions-for-use
Yes 36 (85.7%) 42 (100.0%) 0.0313
No 6 (14.3%) 0 (0.0%)
Successfully completed NXN tasks
per instructions-for-use
Yes 0 (0.0%) 0 (0.0%) NA
No 42 (100.0%) 42 (100.0%)
Comparison of NAI and NXN within each phasea \0.0001 \0.0001
NA not applicable, NAI naloxone 0.4 mg auto-injector, NXN naloxone nasal atomization kit
a McNemar’s Test
Table 7 Adherence to instructions-for-use errors for NAI and NXN
Summary Phase 1 Phase 3
Total participants (n) 42 42
NAI task completion
Remove from outer case 42 (100.0%) 42 (100.0%)
Pull off red safety guard 42 (100.0%) 42 (100.0%)
Place black end against outer thigh 41 (97.6%) 42 (100.0%)
Press ﬁrmly to activate 42 (100.0%) 42 (100.0%)
Hold for at least 5 s 37 (88.1%) 42 (100.0%)
NXN task completion
Remove medication and atomizer 33 (78.6%) 41 (97.6%)
Remove yellow caps from syringe 40 (95.2%) 42 (100.0%)
Remove purple cap from the naloxone cartridge 42 (100.0%) 42 (100.0%)
Attach atomizer by hold wings 0 (0.0%) 2 (4.8%)
Twist or screw naloxone cartridge into syringe 35 (83.3%) 38 (90.5%)
Place cartridge into one nostril to spray*1 mL 0 (0.0%) 28 (66.7%)
Place cartridge to spray*1 mL in other nostril 0 (0.0%) 24 (57.1%)
NAI naloxone 0.4 mg auto-injector, NXN naloxone nasal atomization kit
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the NAI longer than one second, the
minimum, but less than the 5-s countdown.
There were no errors in the adherence to
NAI’s instructions-for-use for during phase 3.
There were 127 errors in adherence to NXN’s
instructions-for-use during phase 1 and 67
errors during phase 3. The main errors in
adherence to NXN’s instructions-for-use
during phase 1 and phase 3 were the
failure to hold the atomizer by the wings
while attaching it to the syringe and the
inability to divide the dose at approximately
1 mL between the two nostrils.
Time to Complete Naloxone
Administration During Phase 1
and Phase 3
The time differences for the study participants
to administer a dose of naloxone to the
simulated patient (Table 8) were significant
when comparing NAI and NXN, with NAI task
time during phase 1 being 0.9 ± 0.25 min and
NXN 6.0 ± 4.76 min (P\0.0001). A large
number of participants (15 of 42) did not
complete the administration tasks using NXN
and by study protocol were assigned the
maximum time of 15 min. This maximum
assignment time was based on the likelihood
that most emergency response personnel would
arrive prior to 15 min since the national
emergency medical service response time is
approximately 9.4 min [14]. Phase 3
(approximately 1 week post-training)
participants’ time differences with the
simulated opioid emergency, showed both
product completion times significantly
improved, with NAI being 0.5 ± 0.15 min and
NXN 2.0 ± 2.15 min (NAI P\0.0001; NXN
P\0.0001).
Table 8 Time to task completion for NAI and NXN
Summary Phase 1 Phase 3 Comparison of
NAI or NXN
between phasesb
Total participants (n) 42 42
NAI total time to complete critical tasks (min)a
N 42 42 \0.0001
Mean (SD) 0.9 (0.25) 0.5 (0.15)
Median 0.9 0.5
Min, Max 0.5, 1.5 0.3, 0.9
NXN total time to complete critical tasks (min)a
N 42 42 \0.0001
Mean (SD) 6.0 (4.76) 2.0 (2.15)
Median 3.6 1.6
Min, Max 1.8, 15.0 0.8, 15.0
Comparison of NAI and NXN within each phaseb \0.0001 \0.0001
NAI naloxone 0.4 mg auto-injector, NXN naloxone nasal atomization kit
a Subject not completing the task counted as 15 min
b Wilcoxon rank-sum test performed as sensitivity analysis
100 Pain Ther (2015) 4:89–105
DISCUSSION
The primary objective of this study was to
compare the usability of NAI and NXN in the
administration of naloxone during a simulated
opioid overdose emergency. The currently
available NXN is primarily distributed and
used by first responders, police, and members
of some harm reduction clinics, but is
increasingly being made available by
pharmacists. NAI has recently been approved
by the FDA for use in the home or non-clinical,
out-of-hospital setting, by caregiver and family
member administration. Nasal atomization kits
are an important tool to help combat the public
health crisis of opioid overdose morbidity and
mortality. Numerous studies have
demonstrated that these kits have saved lives
and that there is a place for a nasally
administered naloxone product in the
emergency treatment of OIRD [8, 15–20]. This
includes populations who are well educated in
manipulating glass syringes and who encounter
frequent opioid overdoses, such as in the harm
reduction community, and trained
professionals such as emergency medical
technicians, law enforcement, and other
trained first responders who are adept at
responding to stressful, emergency situations.
Nasal atomization kits and their
accompanying instructions-for-use have not
been subject to rigorous Human Factors
Engineering development and testing to
evaluate the usability of these kits by the
general population, especially by family
members or caregivers of chronic opioid users.
In addition, the safety and efficacy of the
intranasal route of naloxone administration
has not been subject to FDA review and
approval, including in special populations
such as pediatric patients suffering from
unintentional opioid poisoning. Naloxone is
effective in the treatment of opioid overdose
only if it is: (1) available for administration, (2)
administered correctly by the user, and (3)
administered in a timely fashion as early
intervention is often the determinant outcome
when faced with a life-threatening OIRD event
[21].
Data presenting success of the nasal
naloxone kits have been primarily based upon
qualitative, observational surveys of needle
exchange clinics and other harm reduction
centers that distribute naloxone kits [22].
These surveys collect data based on responses
to questions including the number of overdose
reversals reported over a specific period of time,
but do not ask questions regarding the number
of patients requiring alternative treatment due
to incorrect usage of the naloxone nasal kit or
the number of overdoses that occurred despite
the naloxone nasal kit being dispensed, but not
readily available during the overdose. Despite
initial enthusiasm for the naloxone kit products
and evidence of their life-saving potential,
unanswered questions remain regarding their
availability, usability and effectiveness in
treatment of suspected opioid overdose.
One challenge associated with generic
naloxone products, including vials and
syringes as well as the NXN kit is the lack of
unified instructions-for-use or patient
counseling information [23]. In the case of
this study, the NXN component product
labeling [23] may have confused users,
contributing to Critical Task Errors. For
example, the carton in which the naloxone is
provided for NXN describes use by
‘‘intravenous, intramuscular, or subcutaneous’’
parenteral routes and the pre-filled syringe
looks like a delivery system intended for
parenteral administration (Fig. 1) [23]. This is
an inherent flaw associated with the NXN kits
in which the user is provided written
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instructions and visual cues that are contrary to
the intended nasal use of the product.
Therefore, without the benefit of training,
many participants attempted to mimic
parenteral administration, confusing the
atomizer as a needle. Moreover, the naloxone
carton has a small surface that provides limited
instructions for assembly, but since the
atomization device is included separately, the
instructions have no guidance for its further
assembly onto the pre-filled syringe to create
the finished NXN [23]. Consequently, some
participants either failed to attach the atomizer,
or assembled it incorrectly including cases
where either the atomizer or the glass
cartridge of naloxone was damaged (e.g.,
broken glass) rendering administration
impossible. In addition, in many cases
participants declared that they had completed
the task, believing they had performed a
successful administration of naloxone with
NXN when in fact they had not been
successful. Even after one-on-one, personalized
training and demonstration of correct
administration technique, a substantial
proportion of users were still unable to
correctly administer NXN.
By comparison, NAI contains labeling and
voice instructions that facilitated correct
administration. NAI is self-contained, with
instructions-for-use, including text and
symbols on the flat surface of the product
(Fig. 2) [12]. The product includes a voice
instruction system that assists in guiding users
through the correct administration process.
Therefore, although the supplemental
instructions-for-use documents were not
provided to the participants, the participants
were able to rely on instructions built into the
product. In addition, the administration of
NXN required eight steps compared to five
steps for NAI (Table 2). For NXN, some of the
defined steps required multiple actions such as
removing two caps from the syringe or the
inherent need to remove the different
components from different packages.
Therefore, participants had more opportunities
to fail in adhering to instructions or completing
critical tasks.
The results of this study should be viewed in
light of the limitations of the study and its
specific design to test a ‘‘worst-case’’ scenario.
First, the assignment of Critical Task Errors for
NXN required the determination of a ‘‘clinically
meaningful dose.’’ Because nasally administered
naloxone is not an FDA approved route of
administration, the selection of the dose was
based on published literature in which a full
dose of 1 mL is administered into each nostril
[8, 15–18]. Several studies describe the need for
additional doses of naloxone, therefore, the
study team viewed the full dose of NXN as the
minimally effective amount [24, 25]. Moreover,
administration into both nostrils is listed as a
required step in the instructions-for-use and in
the published clinical studies. Therefore,
administration into both nostrils was deemed
a critical task; however, the study team
permitted administration of a partial dose to
both nostrils to meet the standard for a critical
task, while administration of approximately
1 mL into each nostril was required for
adherence to instructions. It is unknown if
administration of some amount of naloxone
into a single nostril is efficacious in some or all
suspected overdose cases, and it is unknown
how much of the full dose (2 mL) is required to
be administered into the two nostrils to result in
a clinically meaningful benefit. Second, because
this study was designed to evaluate a ‘‘worst-
case’’ scenario, both simulation phases of this
study, before and after training, were conducted
without the benefit of instructions-for-use
leaflets for the participants. There were
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numerous errors associated with the assembly
and administration of NXN which may have
been mitigated if the users had the benefit of
clear visual and written instructions, especially
instructions that replaced those that were on
the outer packaging of the naloxone glass
syringe. However, the likelihood of users for
NXN and NAI to both have access to
instructional leaflets as well as refer to
instructional leaflets during an opioid
overdose emergency is low given the nature of
an opioid overdose emergency.
Despite these study limitations, the data
demonstrates that in a setting where a
layperson is required to administer naloxone,
they have a significantly higher success rate at
administering a clinically meaningful dose
using NAI versus NXN, and they complete the
task utilizing NAI in less time than is required
using NXN. The improved completion time
from phase 1 to phase 3 for NAI and NXN
underscores the effect training has on a user’s
ability to quickly administer each product for
life-threatening OIRD. The success rate and
time-to-administration favor the use of NAI
especially in cases where participants are likely
to have received limited or no training. Even
after training on the proper use of the two
products, results were also statistically
significant in favor of NAI over NXN in terms
of both success rates of administering a
clinically meaningful dose and time of
completion.
Finally, all study participants reported
that they would have confidence in using
NAI in an actual emergency whereas only
one individual, post-training, indicated he
would be confident in using NXN during a
suspected opioid overdose emergency.
Participants attributed their confidence in
using NAI to the limited number of steps
required to complete an injection, the
helpful voice instructions, and the
countdown that indicates when the
injection is complete.
CONCLUSION
This study demonstrated that during a
simulated opioid overdose emergency there
was a statistically significant difference in a
participant’s ability to successfully administer a
simulated dose of naloxone with or without
training or instructional leaflets using NAI as
compared to the NXN. Additionally, this study
demonstrated that no participant could
correctly administer the NXN without
training. Although both products resulted in a
statistically significant reduction in time to
administer a dose following one-on-one
training by a healthcare professional, this
study found that less than 60% of participants
were able to use the NXN as compared to 100%
with the NAI. Residual use errors after training
for NXN were attributed to difficulties
assembling or handling the device, or
remembering to administer the naloxone into
both nostrils of the simulated overdose victim.
This is the first study that has evaluated the
usability of naloxone atomization kits currently
distributed and used in the United States, with
or without comparison to other naloxone
delivery methods. Assembly and use of these
kits is subject to numerous Critical Task Errors
in which the person administering the
naloxone would not provide benefit to the
opioid-related overdose victim. This study
indicates that delivery systems, when adapted
for alternate uses without FDA scrutiny and
approval, may be subject to use-related errors
that could result in a patient not receiving a
potentially life-saving dose of medication.
Additionally, this study demonstrates that
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laypersons are at risk of failure to properly use
the intranasal naloxone delivery system under a
simulated emergency environment.
Early administration of naloxone can be
lifesaving during a suspected opioid
emergency. However, a naloxone formulation
can only be effective during a stressful suspected
opioid emergency if it is readily available and
administered correctly by the user in a timely
manner. Naloxone distribution may become
more widespread in the community due to the
continued increase in opioid-related morbidity
and mortality. This study demonstrates it is
critical that careful design and Human Factors
Engineering be incorporated into the
development of potentially life-saving
naloxone products intended for use by
laypersons in community settings such as the
home. Identification of Critical Task Errors early
in development permit a risk evaluation and the
opportunity to re-design elements that are
subject to the most substantial use-related
errors, or associated with the greatest risk.
This study validated the ability for both trained
and untrained individuals to safely and effectively
administer NAI which fulfills themedical need for
a naloxone product that allows laypersons,
including family members and caregivers, to
administer naloxone hydrochloride in the home
or non-clinical setting during a potentially life-
threatening opioid emergency.
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